Pappula Amrit L, Gibson Louis N, Bouley Renee A, Petreaca Ruben C
The Ohio State University.
MicroPubl Biol. 2022 Sep 27;2022. doi: 10.17912/micropub.biology.000645. eCollection 2022.
SLC6A4 is a serotonin re-uptake transporter which has been a target for anti-depressant therapies but recently some mutations have been described in cancer cells. Here, we characterize mutations in SLC6A4 that appear in cancer cells. We employed several validated computational and artificial intelligence algorithms to characterize the mutations. We identified a previously uncharacterized G100V mutation in lung cancers. structural analysis reveals that this mutation may affect SLC6A4 ligand binding and subsequently its function. We also identified several other mutations that may affect the structure of the protein. This preliminary analysis highlights the role of SLC6A4 in human cancers.
SLC6A4是一种血清素再摄取转运体，一直是抗抑郁疗法的靶点，但最近在癌细胞中发现了一些突变。在此，我们对癌细胞中出现的SLC6A4突变进行了表征。我们采用了几种经过验证的计算和人工智能算法来表征这些突变。我们在肺癌中发现了一种先前未被表征的G100V突变。结构分析表明，这种突变可能会影响SLC6A4配体结合，进而影响其功能。我们还发现了其他几种可能影响蛋白质结构的突变。这项初步分析突出了SLC6A4在人类癌症中的作用。
